PSMD6

Across TCGA pan-cancer cohorts, PSMD6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSMD6 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMD6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMD6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where PSMD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.381	0.794	.001	17	view →
HNSC	DFS	Tertile	All	0.333	0.949	.014	10	view →
LSCC	DFS	Median	All	0.894	0.477	.014	9	view →
PDAC	OS	Median	III,IV	0.294	0.580	.007	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
CCRCC	OS	Quartile	All	0.671	1.000	.008	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSMD6–LUAD (DFS)

Open the LUAD breakdown →